TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06628128: A Long-Term Study of JNT-517 in Participants With Phenylketonuria

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 240 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$2,310,056

Rescue Site Savings

+$1,508,608

Unlock Full NCT06628128 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06628128 Rescue Dossier →